ORION CORPORATION STOCK EXCHANGE RELEASE 6 APRIL 2017 at 9.00 EET
Amendment to Sections 5 and 9(1) of the Articles of Association of Orion Corporation entered in the Trade Register
The amendments of Section 5 and the first paragraph of Section 9 of the Articles of Association of Orion Corporation in accordance with the decision by the AGM held on 22 March 2017 have been entered in the Trade Register. The current Articles of Association are available on the company's website in the address www.orion.fi/articles-of-association. The decisions of the AGM were published in a Stock Exchange Release on 22 March 2017.
| Timo Lappalainen|
President and CEO
| Olli Huotari|
SVP, Corporate Functions
Olli Huotari, SVP, Corporate Functions
tel. +358 50 966 3054
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.